Compare LKFN & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | SDGR |
|---|---|---|
| Founded | 1872 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1997 | 2020 |
| Metric | LKFN | SDGR |
|---|---|---|
| Price | $59.56 | $13.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $67.00 | $24.33 |
| AVG Volume (30 Days) | 179.5K | ★ 1.1M |
| Earning Date | 01-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $257,188,000.00 | $256,951,000.00 |
| Revenue This Year | $12.16 | $23.69 |
| Revenue Next Year | $5.35 | $20.32 |
| P/E Ratio | $14.78 | ★ N/A |
| Revenue Growth | 8.62 | ★ 32.90 |
| 52 Week Low | $50.00 | $14.08 |
| 52 Week High | $70.80 | $28.47 |
| Indicator | LKFN | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 24.15 |
| Support Level | $58.03 | $16.07 |
| Resistance Level | $62.55 | $17.87 |
| Average True Range (ATR) | 1.72 | 0.76 |
| MACD | 0.06 | -0.40 |
| Stochastic Oscillator | 49.96 | 3.88 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.